Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$5.84 -0.3%	$4.97	$1.14 ▼ $7.20	$349.79M	0.8	825,906 shs	453,141 shs
COGT Cogent Biosciences	$12.08	$10.75	$3.72 ▼ $12.97	$1.38B	0.35	1.21 million shs	1.06 million shs
PAHC Phibro Animal Health	$37.07 -3.6%	$29.34	$16.16 ▼ $38.83	$1.50B	0.88	323,934 shs	644,926 shs
SPRY ARS Pharmaceuticals	$11.62 -9.6%	$16.55	$10.00 ▼ $18.90	$1.15B	0.88	2.30 million shs	7.18 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+0.52%	+17.03%	+170.37%	+11.24%
COGT Cogent Biosciences	0.00%	-0.33%	+5.78%	+124.54%	+16.83%
PAHC Phibro Animal Health	0.00%	+14.20%	+39.89%	+50.81%	+78.14%
SPRY ARS Pharmaceuticals	0.00%	-13.93%	-34.28%	-20.84%	-15.43%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALDX Aldeyra Therapeutics	1.8523 of 5 stars	3.3	1.0	0.0	0.0	2.2	1.7	0.6
COGT Cogent Biosciences	3.4425 of 5 stars	4.4	3.0	0.0	0.0	2.8	1.7	0.6
PAHC Phibro Animal Health	4.3154 of 5 stars	1.9	2.0	2.5	1.1	2.1	3.3	3.8
SPRY ARS Pharmaceuticals	2.713 of 5 stars	3.6	0.0	0.0	0.0	2.9	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.67	Moderate Buy	$9.50	62.67% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$19.00	57.28% Upside
PAHC Phibro Animal Health	1.86	Reduce	$28.40	-23.39% Downside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	166.78% Upside

Current Analyst Ratings Breakdown

Latest ALDX, COGT, SPRY, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/29/2025	PAHC Phibro Animal Health	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$19.00 ➝ $27.00
8/28/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$34.00
8/28/2025	PAHC Phibro Animal Health	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/25/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $20.00
8/8/2025	ALDX Aldeyra Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/7/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00
8/6/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $21.00
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$1.19 per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
PAHC Phibro Animal Health	$1.30B	1.16	$3.27 per share	11.34	$7.05 per share	5.26
SPRY ARS Pharmaceuticals	$89.15M	12.88	N/A	N/A	$2.64 per share	4.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$55.85M	-$0.85	N/A	N/A	N/A	N/A	-73.63%	-50.61%	11/6/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.78	N/A	N/A	N/A	N/A	-223.82%	-89.44%	11/11/2025 (Estimated)
PAHC Phibro Animal Health	$48.26M	$1.18	31.42	17.65	0.54	3.73%	32.14%	6.89%	11/5/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.49	N/A	N/A	N/A	-42.74%	-21.85%	-15.88%	11/12/2025 (Estimated)

Latest ALDX, COGT, SPRY, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	Q4 2025	PAHC Phibro Animal Health	$0.52	$0.57	+$0.05	$0.42	$362.24 million	$378.70 million
8/13/2025	Q2 2025	SPRY ARS Pharmaceuticals	-$0.41	-$0.46	-$0.05	-$0.46	$12.92 million	$15.72 million
8/7/2025	Q2 2025	ALDX Aldeyra Therapeutics	-$0.21	-$0.16	+$0.05	-$0.16	$1.08 million	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.29%	N/A	40.68%	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest ALDX, COGT, SPRY, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2025	PAHC Phibro Animal Health	quarterly	$0.12	1.71%	9/3/2025	9/3/2025	9/24/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.86	2.86
COGT Cogent Biosciences	N/A	4.19	4.19
PAHC Phibro Animal Health	2.46	2.76	1.23
SPRY ARS Pharmaceuticals	0.37	6.17	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
COGT Cogent Biosciences	N/A
PAHC Phibro Animal Health	99.34%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	8.50%
COGT Cogent Biosciences	7.29%
PAHC Phibro Animal Health	50.07%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	59.90 million	54.81 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
PAHC Phibro Animal Health	2,475	40.53 million	20.24 million	Optionable
SPRY ARS Pharmaceuticals	90	98.83 million	65.72 million	Optionable

ALDX, COGT, SPRY, and PAHC Headlines

Recent News About These Companies

Epoch Investment Partners Inc. Takes Position in ARS Pharmaceuticals, Inc. $SPRY

August 30 at 5:28 AM | marketbeat.com

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28 at 8:00 AM | globenewswire.com

Vanguard Group Inc. Has $43.88 Million Holdings in ARS Pharmaceuticals, Inc. $SPRY

August 28 at 3:12 AM | marketbeat.com

ARS Pharmaceuticals Inc. (SPRY) Stock Price Today - WSJ

August 24, 2025 | wsj.com

ARS Pharmaceuticals (NASDAQ:SPRY) CFO Sells 12,500 Shares

August 23, 2025 | insidertrades.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 2.3% Following Insider Selling

August 23, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Insider Sells $173,186.32 in Stock

August 22, 2025 | insidertrades.com

Aberdeen Group plc Takes $12.61 Million Position in ARS Pharmaceuticals, Inc. $SPRY

August 21, 2025 | marketbeat.com

Equities Analysts Issue Forecasts for SPRY FY2025 Earnings

August 19, 2025 | marketbeat.com

Leerink Partnrs Issues Negative Forecast for SPRY Earnings

August 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for SPRY Q3 Earnings

August 19, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

August 15, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript

August 14, 2025 | msn.com

ARS Pharma Sales Jump 3,040% in Q2

August 14, 2025 | aol.comA

ARS Pharmaceuticals Inc (SPRY) Q2 2025 Earnings Report Preview: What To Look For

August 14, 2025 | finance.yahoo.com

ARS Pharmaceuticals Reports Strong Growth for neffy

August 14, 2025 | msn.com

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

August 13, 2025 | zacks.com

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

August 13, 2025 | globenewswire.com

Earnings Outlook For ARS Pharmaceuticals

August 12, 2025 | benzinga.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 6.3% - Should You Sell?

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX, COGT, SPRY, and PAHC Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$5.84 -0.02 (-0.34%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.90 +0.07 (+1.11%)

As of 08/29/2025 07:40 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Cogent Biosciences NASDAQ:COGT

$12.08 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$12.08 0.00 (0.00%)

As of 08/29/2025 06:08 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$37.07 -1.39 (-3.61%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$37.06 -0.01 (-0.01%)

As of 08/29/2025 07:17 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

ARS Pharmaceuticals NASDAQ:SPRY

$11.62 -1.24 (-9.64%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$11.65 +0.03 (+0.27%)

As of 08/29/2025 07:49 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time